Kariofyllis holds a Bachelor’s degree (B.Sc.) in Biomedical Sciences at the University of West Attica and subsequently, he has conducted a Master’s degree (M.Sc.) entitled Molecular pharmacology, Biopharmaceutics and Biomolecular analysis at the University of Patras, Greece. His scientific interests are mainly focused on Personalized medicine using newly developed technologies targeting human genetic diseases. In the last three years, Kariofyllis has successfully trained and worked in prestigious Universities and Research Institutes such as the Centre for Genomic Regulation (CRG), Barcelona, Spain, and the King’s College London (KCL), London, United Kingdom, strengthening, even more, his knowledge and skills in the field of Biomedical Science. He currently holds an active position as a visiting research scientist at the Institut de Biologia Evolutiva (IBE) – CSIC UPF and moreover, he is a review editor for Frontiers in Pharmacology and Frontiers in Genetics.
Kariofyllis considers science his life’s call, setting high expectations and goals with a clear vision to become a distinguished scientist.
The GoldenHelix Foundation, London, United Kingdom
University of Patras, Patras, Greece
ORCID ID: https://orcid.org/0000-0002-3085-7799
ESR 14 Project
Standardization of disease and population-specific genotyping panel for preemptive pharmacogenomics: Towards population pharmacogenomics
Kariofyllis will advance the existing knowledge and challenges by developing population-specific genotyping panels for preemptive pharmacogenomics, especially for developing European countries, and to define disease-specific pharmacogenomic panels (e.g. cardiovascular diseases, cancer, neuropsychiatric disorders, etc). These panels will be accompanied by a dedicated web-based translational tool to retrieve, in a dynamic manner from regulators’ guidelines and make them available to physicians for optimizing drug prescriptions for patients based on their pharmacogenomic testing results. This project will adopt a truly multidisciplinary approach, including genome informatics, artificial intelligence, and machine learning. Last but not least, an economic evaluation will also be performed to determine the cost-effectiveness of these panels towards reimbursement of these assays and the reduction of the overall healthcare costs.
Evolutionary Biology, Population Genetics, Pharmacogenomics and Public Health genomics with an emphasis on human disease and novel strategies leading to the identification, understanding, diagnosis, and treatment.
He is passionate about photography and nature considering himself a dedicated traveller. Curiosity about everything is also one of his main interests that reflects with a creative manner into his scientific achievements.